Fenalcomine is a coronary vasodilator, cardiotonic and local anesthetic agent. It was studied in the treatment of angina pectoris.

Gliflumide is a compound with a long-lasting hypoglycemic effect. This blood glucose lowering sulfonamide has shown a large decrease of blood glucose levels in healthy volunteers who where administered the drug orally or intravenously. A very similar reaction but delayed and prolonged response was observed for this drug compared to other insulin secretion-stimulating compounds (such as glibenclamide). High affinity of gliflumide to plasma proteins has been suggested to contribute to this delayed activity.

Cyclexanone is an antitussive drug developed by the Swiss pharmaceutical company Ciba. The compound is claimed to have an analgesic action and an action on central respiratory control.

Dexsecoverine ia an antimuscarinic drug.

Furethidine, a pethidine analog was studied as an analgesic agent. This compound is not currently used in medicine and is listed in schedules of the single convention on narcotic drugs of 1961 as amended by the 1972 protocol.

IQUINDAMINE is an antitussive agent.

Lurtotecan is a semisynthetic analog of camptothecin with antineoplastic activity. It is an inhibitor of DNA topoisomerase I. Liposomal formulation of lurtotecan was being studied in the treatment of cancer. Lurtotecan development has been discontinued.